# ARA-290 (cibinetide)

Source: https://aminodesk.com/library/ara-290
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

ARA-290, also called cibinetide, is a short peptide modeled on part of erythropoietin, the hormone that drives red blood cell production. It was tested for nerve pain in people with sarcoidosis. The small trials were encouraging, but it never reached Phase 3 and its development is inactive.

- **Legal lane:** not FDA-approved. Not one of the six peptides in the October 2026 policy.
- **Evidence grade:** B. Small randomized trials in people; no large confirming trial.
- **Form:** daily injection under the skin in the trials
- **Established human dose:** none approved

## What it is

An 11-amino-acid peptide copied from one surface of erythropoietin. It was designed to switch on a tissue-repair receptor without raising red blood cell counts, which is the effect that makes erythropoietin itself risky to use for repair.

## What the evidence shows

- **Pilot trial:** a randomized, double-blind study in 22 people with sarcoidosis and small fiber neuropathy reported improved nerve symptoms.
- **Dose-ranging trial:** a Phase 2 trial planned for up to 64 people compared three doses with placebo over 28 days. Reports from the program describe more small nerve fibers in the cornea and skin after treatment.
- **Other uses:** Phase 2 work was also done in type 2 diabetes.

These are small, short trials. No Phase 3 trial was started, and the company that developed it has shut down. One drug database lists its clinical status as inactive.

## Legal status

- Not FDA-approved. It received an orphan drug designation for nerve damage in sarcoidosis, which is an incentive for development, not an approval.
- It was never submitted for approval.
- It is not one of the six peptides in the October 2026 compounding policy. What is sold online is a research chemical.

## Reported dosing

**No approved dose exists.**

The dose-ranging trial gave 1 mg, 4 mg or 8 mg under the skin once a day for 28 days. Those are trial doses in a monitored study, not a recommendation.

## Safety

- The trials reported no safety concerns, but they were small and lasted about a month.
- Long-term safety is unknown.
- Nerve symptoms have many causes, some of them treatable. They need a diagnosis before any experiment.
- Products sold as research chemicals have no verified contents or sterility.

## Common questions

### Is ARA-290 FDA-approved?

No. It was never submitted for approval, and its development is inactive.

### What was ARA-290 tested for?

Mainly nerve pain from small fiber neuropathy in people with sarcoidosis, and also type 2 diabetes.

### Does ARA-290 raise red blood cells like EPO?

It was designed not to. It is a fragment of erythropoietin built to act on a repair receptor only.

## Sources

- [Trial record NCT02039687: Phase 2 dose-ranging study of ARA 290 in sarcoidosis](https://ctv.veeva.com/study/study-of-efficacy-of-ara-290-on-corneal-nerve-fiber-density-and-neuropathic-symptoms-of-subjects-wit)
- [EU Clinical Trials Register: the same trial, sponsor Araim Pharmaceuticals](https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003016-45/NL)
- [Superpower: regulatory status and research stage](https://superpower.com/guides/peptides/ara-290)
- [Ozmosi drug profile: clinical status inactive](https://pryzm.ozmosi.com/product/14203)
- [Summary of the 22-person pilot study and the follow-up study](https://www.peptideprotocolwiki.com/peptides/ara-290/research)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
